Compare PEB & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEB | ALMR |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2009 | 2026 |
| Metric | PEB | ALMR |
|---|---|---|
| Price | $18.02 | $31.66 |
| Analyst Decision | Hold | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $13.30 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 266.3K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,475,544,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.53 | N/A |
| 52 Week Low | $9.99 | $21.58 |
| 52 Week High | $19.93 | $38.54 |
| Indicator | PEB | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 46.52 |
| Support Level | $17.50 | $23.69 |
| Resistance Level | $19.73 | $29.06 |
| Average True Range (ATR) | 0.52 | 1.85 |
| MACD | 0.02 | -0.48 |
| Stochastic Oscillator | 61.09 | 22.57 |
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,052 rooms across 44 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under the Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.